{"title":"草本对联药物（二仙）通过减少糖尿病骨质疏松症患者的细胞凋亡，保护成骨细胞免受高糖诱导的损伤：基于网络药理学和实验验证的研究","authors":"","doi":"10.1016/j.eujim.2024.102392","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Traditional Chinese medicine (TCM) has unique advantages in treating diabetic osteoporosis (DOP). This study aimed to explore the mechanisms underlying the protective effects of herb couplet medicines (Erxian) on DOP using network pharmacology and verify these mechanisms using cell experiments.</p></div><div><h3>Methods</h3><p>We used chromatography to analyze the bioactive components of serum containing Erxian couplet medicines (ECMs) and searched for possible targets of the active ingredients in the Traditional Chinese Medicine Systems Pharmacology database. The target proteins of DOP were retrieved from the GeneCards and Online Mendelian Inheritance in Man databases. A component-target network diagram was then constructed using the screened drug components and target information for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. <em>In vitro</em>, cell morphological changes were observed using alkaline phosphatase staining, and the effect of the ECMs on osteoblast viability was assessed using a cell counting kit-8 assay. Finally, the pathway information predicted by network pharmacology was validated using flow cytometry, real-time polymerase chain reaction, and western blot experiments.</p></div><div><h3>Results</h3><p>Twelve types of active ingredients in serum containing ECMs were obtained via chromatography, and 96 potential targets were identified using network pharmacology analysis. Furthermore, GO and KEGG pathway enrichment analyses revealed that the ECMs might participate in the apoptosis signaling pathway in the treatment of DOP. <em>In vitro</em> tests showed that treatment with ECM serum increased osteoblasts’ survival rate and improved the HG group's cell morphology (<em>P</em> < 0.05). BCL2-associated X protein (BAX) expression increased in the HG group but decreased after ECM serum addition (<em>P</em> < 0.05). The expression of B-cell lymphoma-2 (BCL-2) was found to be reduced in the HG group but increased after ECM serum addition (<em>P</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>ECMs can treat DOP via multiple targets and multiple signaling pathways. Moreover, the mechanism underlying the effects of ECMs on osteoblasts was verified by inhibiting apoptotic. The complete signaling pathway requires future study.</p></div>","PeriodicalId":11932,"journal":{"name":"European Journal of Integrative Medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1876382024000611/pdfft?md5=b4332bcaf453e13a8fb5f86481d20f8f&pid=1-s2.0-S1876382024000611-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Herb couplet medicines (Erxian) protect osteoblasts from high glucose-induced damage by reducing cell apoptosis in diabetic osteoporosis: A network pharmacology and experimental verification-based study\",\"authors\":\"\",\"doi\":\"10.1016/j.eujim.2024.102392\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>Traditional Chinese medicine (TCM) has unique advantages in treating diabetic osteoporosis (DOP). This study aimed to explore the mechanisms underlying the protective effects of herb couplet medicines (Erxian) on DOP using network pharmacology and verify these mechanisms using cell experiments.</p></div><div><h3>Methods</h3><p>We used chromatography to analyze the bioactive components of serum containing Erxian couplet medicines (ECMs) and searched for possible targets of the active ingredients in the Traditional Chinese Medicine Systems Pharmacology database. The target proteins of DOP were retrieved from the GeneCards and Online Mendelian Inheritance in Man databases. A component-target network diagram was then constructed using the screened drug components and target information for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. <em>In vitro</em>, cell morphological changes were observed using alkaline phosphatase staining, and the effect of the ECMs on osteoblast viability was assessed using a cell counting kit-8 assay. Finally, the pathway information predicted by network pharmacology was validated using flow cytometry, real-time polymerase chain reaction, and western blot experiments.</p></div><div><h3>Results</h3><p>Twelve types of active ingredients in serum containing ECMs were obtained via chromatography, and 96 potential targets were identified using network pharmacology analysis. Furthermore, GO and KEGG pathway enrichment analyses revealed that the ECMs might participate in the apoptosis signaling pathway in the treatment of DOP. <em>In vitro</em> tests showed that treatment with ECM serum increased osteoblasts’ survival rate and improved the HG group's cell morphology (<em>P</em> < 0.05). BCL2-associated X protein (BAX) expression increased in the HG group but decreased after ECM serum addition (<em>P</em> < 0.05). The expression of B-cell lymphoma-2 (BCL-2) was found to be reduced in the HG group but increased after ECM serum addition (<em>P</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>ECMs can treat DOP via multiple targets and multiple signaling pathways. Moreover, the mechanism underlying the effects of ECMs on osteoblasts was verified by inhibiting apoptotic. The complete signaling pathway requires future study.</p></div>\",\"PeriodicalId\":11932,\"journal\":{\"name\":\"European Journal of Integrative Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1876382024000611/pdfft?md5=b4332bcaf453e13a8fb5f86481d20f8f&pid=1-s2.0-S1876382024000611-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Integrative Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1876382024000611\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Integrative Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876382024000611","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
Herb couplet medicines (Erxian) protect osteoblasts from high glucose-induced damage by reducing cell apoptosis in diabetic osteoporosis: A network pharmacology and experimental verification-based study
Introduction
Traditional Chinese medicine (TCM) has unique advantages in treating diabetic osteoporosis (DOP). This study aimed to explore the mechanisms underlying the protective effects of herb couplet medicines (Erxian) on DOP using network pharmacology and verify these mechanisms using cell experiments.
Methods
We used chromatography to analyze the bioactive components of serum containing Erxian couplet medicines (ECMs) and searched for possible targets of the active ingredients in the Traditional Chinese Medicine Systems Pharmacology database. The target proteins of DOP were retrieved from the GeneCards and Online Mendelian Inheritance in Man databases. A component-target network diagram was then constructed using the screened drug components and target information for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. In vitro, cell morphological changes were observed using alkaline phosphatase staining, and the effect of the ECMs on osteoblast viability was assessed using a cell counting kit-8 assay. Finally, the pathway information predicted by network pharmacology was validated using flow cytometry, real-time polymerase chain reaction, and western blot experiments.
Results
Twelve types of active ingredients in serum containing ECMs were obtained via chromatography, and 96 potential targets were identified using network pharmacology analysis. Furthermore, GO and KEGG pathway enrichment analyses revealed that the ECMs might participate in the apoptosis signaling pathway in the treatment of DOP. In vitro tests showed that treatment with ECM serum increased osteoblasts’ survival rate and improved the HG group's cell morphology (P < 0.05). BCL2-associated X protein (BAX) expression increased in the HG group but decreased after ECM serum addition (P < 0.05). The expression of B-cell lymphoma-2 (BCL-2) was found to be reduced in the HG group but increased after ECM serum addition (P < 0.05).
Conclusion
ECMs can treat DOP via multiple targets and multiple signaling pathways. Moreover, the mechanism underlying the effects of ECMs on osteoblasts was verified by inhibiting apoptotic. The complete signaling pathway requires future study.
期刊介绍：
The European Journal of Integrative Medicine (EuJIM) considers manuscripts from a wide range of complementary and integrative health care disciplines, with a particular focus on whole systems approaches, public health, self management and traditional medical systems. The journal strives to connect conventional medicine and evidence based complementary medicine. We encourage submissions reporting research with relevance for integrative clinical practice and interprofessional education.
EuJIM aims to be of interest to both conventional and integrative audiences, including healthcare practitioners, researchers, health care organisations, educationalists, and all those who seek objective and critical information on integrative medicine. To achieve this aim EuJIM provides an innovative international and interdisciplinary platform linking researchers and clinicians.
The journal focuses primarily on original research articles including systematic reviews, randomized controlled trials, other clinical studies, qualitative, observational and epidemiological studies. In addition we welcome short reviews, opinion articles and contributions relating to health services and policy, health economics and psychology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
